- Home
- IPHA vs LAZR Comparison
IPHA vs LAZR Comparison
Compare IPHA & LAZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- LAZR
- Stock Information
- Founded
- IPHA 1999
- LAZR 2012
- Country
- IPHA France
- LAZR United States
- Employees
- IPHA N/A
- LAZR N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- LAZR Auto Parts:O.E.M.
- Sector
- IPHA Health Care
- LAZR Consumer Discretionary
- Exchange
- IPHA Nasdaq
- LAZR Nasdaq
- Market Cap
- IPHA 160.1M
- LAZR 176.7M
- IPO Year
- IPHA 2019
- LAZR N/A
- Fundamental
- Price
- IPHA $2.16
- LAZR $1.71
- Analyst Decision
- IPHA Strong Buy
- LAZR Hold
- Analyst Count
- IPHA 1
- LAZR 5
- Target Price
- IPHA $11.00
- LAZR $15.25
- AVG Volume (30 Days)
- IPHA 6.4K
- LAZR 4.2M
- Earning Date
- IPHA 09-17-2025
- LAZR 08-12-2025
- Dividend Yield
- IPHA N/A
- LAZR N/A
- EPS Growth
- IPHA N/A
- LAZR N/A
- EPS
- IPHA N/A
- LAZR N/A
- Revenue
- IPHA $20,831,349.00
- LAZR $72,496,000.00
- Revenue This Year
- IPHA $350.96
- LAZR $5.70
- Revenue Next Year
- IPHA $32.92
- LAZR $14.14
- P/E Ratio
- IPHA N/A
- LAZR N/A
- Revenue Growth
- IPHA N/A
- LAZR N/A
- 52 Week Low
- IPHA $1.29
- LAZR $1.69
- 52 Week High
- IPHA $3.51
- LAZR $18.60
- Technical
- Relative Strength Index (RSI)
- IPHA 52.85
- LAZR 28.47
- Support Level
- IPHA $2.04
- LAZR $1.73
- Resistance Level
- IPHA $2.20
- LAZR $2.04
- Average True Range (ATR)
- IPHA 0.10
- LAZR 0.15
- MACD
- IPHA -0.02
- LAZR -0.04
- Stochastic Oscillator
- IPHA 33.83
- LAZR 3.10
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About LAZR Luminar Technologies Inc.
Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.